FDA Misses Congressionally Mandated Deadline to Publish Cannabinoid Lists

FDA MISSES THE MOST IMPORTANT DEADLINE IN HEMP HISTORY

The Feb 10 deadline came and went. The FDA published nothing.

Congress mandated that within 90 days of the Nov 2025 spending bill, the FDA would publish lists classifying every known cannabinoid—naturally occurring, THC-class, and those with ‘similar effects.’ The agency was also supposed to clarify the term ‘container,’ which determines how the 0.4mg THC limit applies to actual products.

None of it materialized. HHS told reporters they intended to meet the deadline, but the lists never appeared in the Federal Register.

The significance cannot be overstated. These lists will determine which cannabinoids survive federal regulation and which are treated as controlled substances. Without them, the industry operates in a compliance vacuum as the Nov 12 cliff approaches.

Stakeholders are using the missed deadline to argue for a delay. The HEMP Act and the Hemp Planting Predictability Act both offer alternatives. But the FDA’s failure to perform its most basic obligation under the new law raises a more fundamental question: if the agency can’t even classify cannabinoids on time, how will it enforce a sweeping prohibition in nine months?